Helicobacter pylori eradication cost-benefit: the case against.
Helicobacter pylori is an important human pathogen, implicated in the pathogenesis of peptic ulcer disease, gastric cancer, and perhaps also in other non-gastrointestinal disease. There is little doubt that in peptic ulcer disease at least, there is a strong argument for its eradication on both clinical and economic terms. The majority of subjects infected with Helicobacter pylori never develop clinically overt disease, and it is this group that the clinical and financial benefit of eradication needs to be closely examined.
Patchett
S E
SE
Digestive Diseases Research Centre, St Bartholomew's, London, UK.
D003362:Cost-Benefit Analysis; D016481:Helicobacter Infections / Q000517:prevention & control*; D016480:Helicobacter pylori / Q000472:pathogenicity*; D006801:Humans; D008875:Middle Aged; D012008:Recurrence; D013045:Species Specificity; D013272:Stomach Diseases / Q000382:microbiology* / Q000517:prevention & control